On Monday, Tempus AI stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 87, up from 79 the day before. The healthcare technology stock debut on June 14.
This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Is Tempus AI Stock A Buy?
Since hitting a 52-week high intraday high of 77 on Aug. 22, Tempus AI stock has pulled back and bouncing off its 50-day moving average. While the stock is not near an ideal entry right now, see if it is able to form and break out from a proper chart pattern.
The Chicago, Ill.-based healthcare tech company reported 0% earnings growth in its most recent report. Revenue rose 25%.
Tempus AI stock earns the No. 22 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Catalent are among the top 5 highly rated stocks within the group.
